Anatara Lifesciences (ASX:ANR) said it is unlikely to achieve a statistically significant improvement in irritable bowel syndrome severity scoring system when compared to placebo in the second stage of the phase two Gastrointestinal ReProgramming-IBS trial based on preliminary analysis, according to a Monday Australian bourse filing.
It said the second stage of the trial moved into the database lock process after all participants completed the mandatory two-week follow-up period.
The final fully assessable number of participants has been reduced to 62 from 71 after the assessment of participant numbers for both compliance and entry criteria.
The second stage included a planned extension of the phase two trial, following the successful completion of stage 1 which reported on 20 patients with a greater than 50% reduction in IBS symptoms and with a safety profile confirmed.
It added that its planned anti-obesity in-vivo pre-clinical experiments are now underway following agreements with the University of Newcastle.
Its shares fell 74% in recent trading on Monday, reaching an all-time low.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。